DPYSL5 and paraneoplastic neurologic syndrome: The involvement of CRMP5 in cancer was first identified when the CRMP5 autoimmune antibody was detected in the sera of patients with paraneoplastic neurological syndrome, usually associated with small cell lung cancer and, less frequently, thymoma (57).